Dermata Therapeutics Inc SEC Filings

DRMA is updating its at-the-market stock offering program to allow additional sales of its common stock with an aggregate offering price of up to $705,000 through H.C. Wainwright & Co. under an existing Form S-3 shelf. This amount is in addition to approximately $3,454,390 of common stock previously sold under earlier prospectus supplements. The filing reflects the limits of General Instruction I.B.6 of Form S-3, which restricts primary offerings to no more than one-third of public float in any 12-month period while public float is below $75.0 million. The company reports a public float of about $7,493,999, based on 2,386,624 shares held by non-affiliates as of January 23, 2026, at a reference price of $3.14 per share, and notes that about $1,792,248 of securities have been sold under these limits in the last twelve months.

Dermata Therapeutics, Inc. is registering up to 6,207,730 shares of common stock for resale by existing investors under a Form S-3 registration statement. These shares include 1,484,312 common shares plus shares issuable upon exercise of 537,750 pre-funded warrants, 2,022,062 Series C warrants, 2,022,062 Series D warrants, and 141,544 placement agent warrants, all issued in a December 29, 2025 private placement. Dermata will not receive proceeds from stockholder resales but would receive cash only if the warrants are exercised, which it plans to use for working capital and general corporate purposes.

The company describes a major strategic shift from prescription dermatology to over-the-counter, science-backed products built on its Spongilla technology, with an initial once-weekly topical acne kit targeted for launch in mid-2026. Dermata also notes a 1-for-10 reverse stock split effective August 1, 2025 and highlights Nasdaq listings for its common stock and public warrants under the symbols “DRMA” and “DRMAW.”

Dermata Therapeutics, Inc. is shifting its strategy to focus on over-the-counter dermatology products that can be sold directly to consumers. The company plans to start with a once-weekly acne kit that combines an approved OTC monograph active ingredient with its Spongilla technology, targeting a launch in the middle of 2026, with additional OTC products expected afterward. As part of this pivot into the OTC marketplace, Dermata has withdrawn its investigational new drug application for XYNGARI™ with the U.S. Food and Drug Administration, moving away from that regulated prescription development path.

Dermata Therapeutics, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price listing rule. The company had previously been notified on May 14, 2025 that its common stock failed to meet the $1.00 per share minimum bid price requirement for 30 consecutive business days and that, because it had implemented a reverse stock split within the prior year, its securities were subject to potential delisting from the Nasdaq Capital Market.

After Dermata requested a hearing and was granted an exception until August 14, 2025 to regain compliance, Nasdaq staff notified the company on August 22, 2025 that it once again satisfies the minimum bid price requirement and that the matter is closed. This removes the previously disclosed risk that Dermata’s securities could be suspended or delisted from Nasdaq based on the minimum bid price issue.

Armistice Capital, LLC and Steven Boyd report beneficial ownership of 672,134 shares of Dermata Therapeutics, representing 9.99% of the class. The filing states Armistice Capital acts as investment manager to a Master Fund that directly holds the shares and that Armistice and Mr. Boyd share voting and dispositive power over those shares. The Master Fund is described as the direct holder but disclaims beneficial ownership due to its investment management agreement. The filing affirms the position is held in the ordinary course of business and not for the purpose of changing control.

Dermata Therapeutics, Inc. reported unaudited second-quarter financials showing total assets of $6.64 million and cash and cash equivalents of $6.48 million as of June 30, 2025, which the company says will fund operations into the second quarter of 2026. The company recorded a net loss of $4.0 million for the six months ended June 30, 2025, and had an accumulated deficit of $69.7 million. Equity financing activity in early 2025 provided material cash inflows, including net proceeds of approximately $5.7 million from a warrant inducement and approximately $2.2 million from a January 2025 PIPE.

Clinical update: Dermata announced that its XYNGARI(TM) Phase 3 STAR-1 trial met all co-primary endpoints at week 12, with inflammatory lesion reductions of -16.8 versus -13.1 for placebo, noninflammatory lesion reductions of -17.3 versus -12.4 for placebo, and IGA responder rates of 29.4% versus 15.2% for placebo. Management notes a second Phase 3 trial (STAR-2) is required by the FDA. The company also discloses supply concentration risk (a Russian supplier) and Nasdaq minimum bid non-compliance with an exception period granted through August 14, 2025, creating ongoing listing risk.

On August 13, 2025 Dermata Therapeutics, Inc. submitted a Current Report on Form 8-K to furnish a press release that provides a corporate update and reports second quarter 2025 financial results for the quarter ended June 30, 2025. The filing identifies the press release as Exhibit 99.1 and an Interactive XBRL cover page as Exhibit 104. The company states the information in Item 2.02 and Exhibit 99.1 is furnished, not "filed," and therefore is not subject to Section 18 liability or automatically incorporated by reference into future filings. The report is signed by CEO Gerald T. Proehl.